Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Year: 2025
Type: erratum
Abstract: In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases ( N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases ( N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases ( N = 14); 2.8 (1.8, 7.4)” the row originally read “Liver metastases ( N = 14); 2.8 (1.8, 5.3)” The change is reflected in the HTML and PDF versions of the article.
Source: Nature Communications
Authors: R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Institutions: Imperial College London, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, University of Oxford, Guy's and St Thomas' NHS Foundation Trust, Oregon Health & Science University, OHSU Knight Cancer Institute, University of Liverpool, University of California, Los Angeles, Northwestern University, Oncology Hematology Care, Baylor University Medical Center, University of Arizona Cancer Center, Sarah Cannon Research Institute, Cancer Research UK, Cancer Research UK Cambridge Center, Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W4408199928